Core Viewpoint - Dongyang Sunshine Pharmaceutical (06887) has applied for the listing and trading of 112.7 million H-shares on the Hong Kong Stock Exchange, based on the assumption that all shareholders will convert their shares according to the exchange ratio and merger agreement [1][2] Group 1 - The company plans to privatize Dongyang Sunshine Changjiang Pharmaceutical by issuing H-shares as consideration to acquire the H-shares held by shareholders, with a conversion ratio of 0.263614 new H-shares for each H-share of Dongyang Sunshine Changjiang Pharmaceutical [2] - A special dividend of HKD 1.50 per share will be paid to shareholders of Dongyang Sunshine Changjiang Pharmaceutical, who collectively hold approximately 427.6 million shares, upon the completion of the privatization [2] - Upon completion of the privatization, Dongyang Sunshine Changjiang Pharmaceutical's listing status on the exchange will be revoked, and the company will assume all assets, liabilities, and rights of Dongyang Sunshine Changjiang Pharmaceutical [2] Group 2 - The H-shares will be eligible securities for Hong Kong clearing once approved for listing and trading, allowing for deposit, settlement, and transfer in the central clearing system [3]

Core Viewpoint - Dongyangguang Pharmaceutical Co., Ltd. is advancing towards its Hong Kong IPO while facing challenges with its core product, Oseltamivir Phosphate capsules, which have been suspended from the Zhejiang medical insurance network, potentially impacting revenue significantly [1][6][8]. Group 1: Company Overview - Dongyangguang Pharmaceutical is a comprehensive pharmaceutical company engaged in the research, production, and commercialization of drugs, focusing on infection, chronic diseases, and oncology [3]. - The company plans to list on the Hong Kong main board through a merger with its subsidiary, Dongyangguang Changjiang Pharmaceutical, without raising new funds [3]. Group 2: Financial Performance - Revenue for Dongyangguang Pharmaceutical from 2022 to 2024 is projected to be approximately CNY 3.814 billion, CNY 6.386 billion, and CNY 4.019 billion, respectively [4]. - The company's net profit for the same period is expected to be CNY -1.416 billion, CNY 1.014 billion, and CNY 24.8 million, indicating a significant fluctuation in profitability [4]. Group 3: Product and Market Dynamics - Oseltamivir Phosphate is the company's core product, accounting for 81.2%, 86.9%, and 64.2% of annual revenue from 2022 to 2024 [8]. - The product's revenue is under pressure due to increased competition, with market share dropping from 64.8% in 2023 to 54.8% in 2024, a decline of 10 percentage points [10][12]. Group 4: Market Challenges - The suspension of the "Kewai" Oseltamivir Phosphate capsules from the medical insurance network may adversely affect market share and sales revenue [6][8]. - The competitive landscape includes over 120 companies in the domestic antiviral drug market, intensifying the pressure on Dongyangguang Pharmaceutical [8][12]. Group 5: Future Prospects - The company is diversifying its portfolio, with ongoing developments in diabetes and oncology treatments, which may provide growth opportunities beyond its core antiviral products [12].

今日导读 1.近日，中央金融委员会印发《关于支持加快建设上海国际金融中心的意见》。 2. 6月18日，中国证监会发布实施《关于在科创板设置科创成长层增强制度包容性适应性的 意见》。 3.6月18日，京东旅行发布致全体酒店经营者的一封公开信。公开信显示，酒店商家参与"京 东酒店PLUS会员计划"，享受最高三年0佣金。 2、6月18日，中国证监会发布实施《关于在科创板设置科创成长层增强制度包容性适应性的意见》， 在持续抓好"科创板八条"落地实施的基础上，以设置专门层次为抓手，重启未盈利企业适用科创板第 五套标准上市，推出一揽子更具包容性、适应性的制度改革，着力打通支持优质科技型企业发展的堵 点难点，同时进一步加强投资者合法权益保护。 3、6月18日，金融监管总局局长李云泽在2025陆家嘴论坛上表示，当前中国家庭的现金和储蓄占比超 过一半。随着居民财富持续积累，财富管理需求向多元化专业化配置转型。支持外资机构在理财投 资、资产配置、保险规划等领域加大布局。 4、6月18日，中国人民银行行长、论坛共同轮值主席潘功胜在2025陆家嘴论坛上表示，新型技术推动 央行数字货币、稳定币蓬勃发展，大幅缩短跨境支付链条，也对金融监 ...

Market Overview - The Hong Kong stock market for innovative drugs has seen a strong rebound in 2023, with the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index (HSSCPB) achieving a year-to-date increase of 71.83%, contrasting sharply with a decline of 20.74% in the same period last year [1] - The Hong Kong innovative drug ETF (159567) also recorded a significant growth of 67.16% [1] - The ongoing recovery in the secondary market has created new opportunities for numerous pharmaceutical companies seeking to go public, leading to a surge in IPO activity in Hong Kong [1] IPO Activity - In June alone, seven local pharmaceutical companies, including Hansai Aitai, Weili Zhibo, Yinnuo Pharmaceutical, Dongyangguang Pharmaceutical, Changfeng Pharmaceutical, Hemei Pharmaceutical, and Xuanzhu Biological, have submitted applications for listing in Hong Kong [1] - Notably, several of these companies, such as Hansai Aitai, Weili Zhibo, Yinnuo Pharmaceutical, Hemei Pharmaceutical, and Xuanzhu Biological, are still in a loss-making state [1] - The trend of companies transitioning from A-share IPO attempts to Hong Kong listings is evident, as seen with Changfeng Pharmaceutical and Xuanzhu Biological [1] Financial Performance of IPO Candidates - Hansai Aitai reported revenues of 6.664 million yuan and 7.681 million yuan for 2023 and 2024, respectively, with losses of 85.16 million yuan and 116.92 million yuan [2] - Weili Zhibo's revenue for 2023 was 8.865 million yuan, with losses of 36.2249 million yuan and 30.1216 million yuan for 2023 and 2024 [2] - Yinnuo Pharmaceutical generated revenues of 16.849 million yuan and 20.055 million yuan for 2023 and 2024, with losses of 73.3376 million yuan and 17.469 million yuan [2] Industry Trends - The Hong Kong IPO market is becoming increasingly attractive for Chinese pharmaceutical companies due to more flexible and lenient listing conditions compared to the A-share market [2] - The introduction of the "18A" listing rule in 2018 has opened doors for unprofitable biotech companies, fueling the IPO wave among innovative drug companies [3] - The current phase of the pharmaceutical industry is characterized by a "structural thaw," where companies with genuine innovation are beginning to attract financing [3] Challenges for Innovative Drug Companies - Many companies, including Hansai Aitai, face significant challenges due to high R&D costs and prolonged timelines for drug development [4] - The average success rate for drug development from Phase I to FDA approval is only 7.9%, with a lengthy average timeline of 10.5 years [4] - Companies like Weili Zhibo are also navigating uncertainties, having lost significant business development (BD) projects just before their IPO [6] Competitive Landscape - Companies with commercialized products, such as Yinnuo Pharmaceutical and Xuanzhu Biological, are also facing intense market competition and product iteration pressures [8] - Yinnuo Pharmaceutical's flagship product, approved for treating type 2 diabetes, has not yet turned the company profitable, with losses of 73.3 million yuan and 17.5 million yuan projected for 2023 and 2024 [8] - Dongyangguang Pharmaceutical, despite its market leadership, is confronting risks associated with expiring patents, particularly for its key product [9] Strategic Focus - Dongyangguang Pharmaceutical aims to enhance operational efficiency and explore new growth avenues through the integration of its R&D platform and product pipeline [9] - Changfeng Pharmaceutical plans to invest raised funds into the full-cycle R&D and commercialization of inhalation formulations, as well as upgrading production facilities [9] - The overall expectation is that both loss-making and established companies will leverage the Hong Kong listing to navigate the competitive landscape of the biopharmaceutical industry [10]

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical industry, indicating that the industry is expected to outperform the benchmark index over the next 12 months [33]. Core Insights - The pharmaceutical sector is experiencing a recovery, with significant growth in sub-sectors such as internet healthcare, biotechnology, and medical devices, which saw increases of 36%, 34%, and 24% respectively in February 2025 [3][6]. - The report highlights the government's encouragement of innovative drug development, including discussions on expanding payment channels for innovative drugs and the potential establishment of a category for innovative drugs in the insurance framework [4][24]. - The medical device market is showing signs of recovery, with the domestic medical imaging equipment market growing over 47% year-on-year in January 2025, and an increase in the number of CT devices awarded contracts by 4.2% compared to the previous year [4][30]. Market Review - In February 2025, the Hang Seng Composite Industry Index rose by 12.8%, while the Hang Seng Healthcare Index increased by 16.3%, outperforming the market by 3.5 percentage points [3][6]. - The A-share market saw the Shanghai and Shenzhen 300 Index decline by 3% in January, with the pharmaceutical and biotechnology index dropping by 3.8%, but rebounding in February with a 5.1% increase [14]. - The report notes that all 13 sub-sectors in the pharmaceutical industry experienced declines in January, but several sub-sectors, including hospitals and medical devices, showed significant gains in February [14]. Industry Data Update - The report indicates that the basic medical insurance revenue for January 2025 reached 314.3 billion yuan, a year-on-year increase of 10.4%, with expenditures growing by 8.5% [17]. - The commercial health insurance sector is also expanding, with original premium income reaching 977.3 billion yuan in 2024, reflecting an 8.2% year-on-year growth [20]. - Medical device exports, particularly for ECG recorders, ultrasound diagnostic devices, and CT machines, have accelerated in both quantity and value since the second half of 2024 [21]. Industry News Summary - The National Healthcare Security Administration held a meeting to support innovative drug development, engaging with major pharmaceutical companies to discuss strategies for enhancing the market for innovative drugs [23][24]. - A draft opinion on improving the drug pricing mechanism has circulated, proposing measures to support innovative drug development and enhance drug accessibility [28]. - The report mentions ongoing efforts to regulate prices in the healthcare sector, including a comprehensive governance initiative for central venous catheter pricing, which has led to significant price reductions for related medical services [29][30].